Aims: Elevated pancreatic enzyme can be observed in the course of coronavirus disease-2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Here, we aimed to determine the frequency of lipase elevation in the course of COVID-19 and examine its effect on disease outcomes.
Methods: Of 42742 patients with the positivity of SARS-CoV-2 reverse transcriptase-polymerase chain reaction test (RT-PCR), 3167 undergoing lipase tests were included. The relationship between patients’ clinical features, development of acute pancreatitis (AP), and mortality rates was investigated.
Results: Higher lipase levels than normal limits were found in 399 (12.6%) patients. Lipase levels were three times higher than the normal limit in 119 (3.8%) patients; compared to the rest of the patients, patients’ age (62.8±17.9 vs 52.1±17.9 years, p<0.001), and rates of male patients (58% vs 45%, p=0.006) and mortality (17.6% vs 8%, p=0.001 respectively) were higher. Thirty-two (1.01%) patients were diagnosed with acute pancreatitis (AP). As lipase levels elevated, hospitalization (p<0.001) and requirement for intensive care unit (p=0.002) also increased. A total of 264 (8.3%) patients died, and mortality rates were higher in males (11% vs 6%, p<0.001). The dead were older (72.0±12.3 years vs 50.7±17.4 years, p<0.001). There was a linear positive correlation between patients’ age (p<0.001), lipase levels (p<0.001), and mortality. Mortality was increased among men and in the presence of AP (p<0.001).
Conclusion: Pancreatic enzyme levels should be measured in the course of COVID-19 due to increased mortality in patients of advanced age, males with AP, and high lipase levels.
Coronavirus disease 2019 COVID-19 lipase pancreas pancreatitis SARS-CoV-2
BU ÇALIŞMAMIZ, UŞAK ÜNİVERSİTESİ TIP FAKÜLTESİ KLİNİK ARAŞTIRMALAR ETİK KURULU'NUN, 25.05.2023 TARİHLİ VE 89-89-12 NUMARALI ETİK KURUL İZNİ İLE GERÇEKLEŞTİRİLMİŞTİR.
Birincil Dil | İngilizce |
---|---|
Konular | İç Hastalıkları |
Bölüm | Orijinal Makale |
Yazarlar | |
Yayımlanma Tarihi | 25 Mart 2024 |
Gönderilme Tarihi | 1 Ocak 2024 |
Kabul Tarihi | 10 Mart 2024 |
Yayımlandığı Sayı | Yıl 2024 |
Üniversitelerarası Kurul (ÜAK) Eşdeğerliği: Ulakbim TR Dizin'de olan dergilerde yayımlanan makale [10 PUAN] ve 1a, b, c hariç uluslararası indekslerde (1d) olan dergilerde yayımlanan makale [5 PUAN]
Dahil olduğumuz İndeksler (Dizinler) ve Platformlar sayfanın en altındadır.
Not: Dergimiz WOS indeksli değildir ve bu nedenle Q olarak sınıflandırılmamıştır.
Yüksek Öğretim Kurumu (YÖK) kriterlerine göre yağmacı/şüpheli dergiler hakkındaki kararları ile yazar aydınlatma metni ve dergi ücretlendirme politikasını tarayıcınızdan indirebilirsiniz. https://dergipark.org.tr/tr/journal/2316/file/4905/show
Dergi Dizin ve Platformları
Dizinler; ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, vs.
Platformlar; Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons vs.